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Materials and Methods: We evaluated 22 women diagnosed with 
cervical cancer that had undergone pre and post treatment FDG-PET. 
Patients were treated with standard doses of concomitant chemo-
radiotherapy in our department from 2005-2012. Using deformable 
image registration and dose remapping technology (Velocity AI 
software), we delineated total (BMtot) and active BM (BMact) volumes 
receiving >1 Gy on the radiotherapy planning image sets, combining 
dose matrix data of treatment planning and PET images. Minimum, 
mean, and maximum SUVs and dose maximum (Dmax), mean, volume 
receiving 10 Gy (V10), V20, V30, V40 were computed on BMtot and 
BMact separately using initial and after treatment (response) PET’s, 
respectively. Hemograms before the treatment start, during the acute 
toxicity period (nadirs), 3 months after the treatment (response PET), 
and at the late follow-up period were obtained. 
Results: Mean volumetric BMact/BMtot ratio was 45.6%. In two-tailed 
Student’s t-Test, initial /response SUV rates were 73% and 60% for 
BMtot and BMact, respectively; with significant reduction (p < 0.001). 
In two-tailed sign test, all dosimetric parameters of BMtot and BMact 
were different (p < 0.001) except Dmax. Significant correlations were 
observed in pairwise analysis between inital SUV values and acute 
hematologic nadirs; response SUV measurements and response PET 
hematological values, respectively (p < 0.05). Effects of varied 
parameters were found on acute and response PET hemograms in 
multiple logistic regression analysis but not on the hemograms of the 
last follow-ups. 
Conclusions: Our novel method to delineate and measure active bone 
marrow in radiation oncology combining deformable registration, 
metabolic imaging, and dose remapping can allow creating new 
models to predict both acute and late toxicity. Further analysis of this 
approach will be done with a larger cohort.  
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Purpose/Objective: To evaluate the patterns of nodal failure 
(recurrences and persistent disease) in patients with locally advanced 
cervix cancer. 
Materials and Methods: EMBRACE is a multicenter prospective 
observational study to investigate the impact of MRI guided 3D 
brachytherapy on outcome in locally advanced cervix cancer. 
Treatment consists of a combination of external beam radiotherapy 
(EBRT), MRI guided brachytherapy and concomitant chemotherapy. 
According to the protocol all elective pelvic nodal regions are treated 
with 45-50 Gy EBRT and macroscopic pathological nodes are boosted 
to about 60 Gy. Elective para-aortic irradiation to L1-L2 is given if 
pathological nodes are found at the level of common iliac or higher. 
This study includes 493 consecutive patients FIGO stage IB to IVB (with 
nodal involvement up to L2), included from November 2008 till July 
2011 with a median follow-up of 14 months. Cox regression analysis 
was performed comparing patients with and without nodal 
recurrences.  
Results: Lymph node involvement at time of diagnosis was present in 
235 patients (50%). 215 patients (46%) had suspicious nodes in the 
lower iliac (external/internal iliac), 70 patients (15%) in the common 
iliac and 39 patients (8.4%) in the para-aortic region. The highest level 
of verification was radiology in 38%, PET-CT in 35% and pathology in 
27%. The 2-year actuarial rate for nodal failure was 11%. Nodal failure 
occurred in 56 patients, 7 of which had persistent nodal disease, with 
median time to detection being 9 months (range 1-34 months). More 
than one lymph node region was involved in 45% of the patients. Nodal 
failures were present in 15% of node positive patients and 8% of node 
negative patients. Most nodal failures were located in the para-aortic 
region (n=35, 62%), with 77% of them being outside the radiation 
fields. Nodal failures in the lower iliac and the common iliac region 
occurred in respectively 39% (n=22) and 27% (n=15), all of which inside 
the elective treatment fields. In multivariate analysis the only 
predictive factors for nodal failure were tumour diameter ≥ 5 cm 
(p=.03) and presence of lymph nodes at time of diagnosis (especially if 
PET-CT positive or pathologically proven) (p=.003).  
 
  
Conclusions: Suspicious or proven nodal disease at time of diagnosis 
was seen in 50% of the patients with locally advanced cervix cancer. 
Tumour diameter ≥ 5 cm and nodal disease at time of diagnosis were 
predictive factors for nodal failure. Nodal disease at time of diagnosis 
was located mostly in the lower iliac, whereas nodal failures were 
located mostly in the para-aortic region. The majority of para-aortic 
recurrences occurred outside the radiation field, suggesting a deficit 
in treated volume due to suboptimal detection of clinical disease. 
Future work will focus on improved detection of nodal disease at time 
of diagnosis and on a more detailed analysis of dose volume effects 
with longer FU. 
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Purpose/Objective: Whole-pelvis concurrent chemoradiation (WP-
CCRT) is the standard treatment option for patients with locally 
advanced cervical cancer. However WP-CCRT could not decrease the 
para-aortic nodal recurrences, so our aim was to evaluate whether 
extended field concurrent chemoradiation (EF-CCRT) leads to results 
better to those obtained by standard WP-CCRT in locally advanced 
cervical cancer with radiologic negative para-aortic lymph nodes 
(PALN). 
Materials and Methods: Patient eligibility included histopathologically 
proven squamous cell carcinoma, adenocarcinoma or adeno-squamous 
cell carcinoma; radiologic negative PALN locally advanced cervical 
cancer stages IIB-IVA with normal hematologic, renal,and liver 
functions. Between July 2007 and April 2008, 82 were 
accrued.Patients were randomly assigned to WP-CCRT (40 patients) 
